EC Number |
Inhibitors |
Structure |
---|
3.6.1.54 | 1-(5-((4-(3-(trifluoromethyl) phenyl)piperazin-1-yl) sulfonyl)indolin-1-yl)ethan-1-one |
47.2% residual activity at 0.002 mM, 23.5% residual activity at 0.006 mM, 14.1% residual activity at 0.01 mM, 11.7% residual activity at 0.05 mM |
|
3.6.1.54 | 1-(5-[4-[3-(propan-2-yl)phenyl]piperazine-1-carbonyl]-2,3-dihydro-1H-indol-1-yl)ethan-1-one |
29% residual activity at 0.01 mM |
|
3.6.1.54 | 1-(5-[4-[3-(trifluoromethyl)phenyl]-1,4-diazepane-1-sulfonyl]-2,3-dihydro-1H-indol-1-yl)ethan-1-one |
94% residual activity at 0.01 mM |
|
3.6.1.54 | 1-(5-[4-[3-(trifluoromethyl)phenyl]piperazine-1-sulfonyl]-2,3-dihydro-1H-indol-1-yl)ethan-1-one |
6.0% residual activity at 0.01 mM |
|
3.6.1.54 | 1-[5-(4-phenylpiperazine-1-sulfonyl)-2,3-dihydro-1H-indol-1-yl]ethan-1-one |
32% residual activity at 0.01 mM |
|
3.6.1.54 | 1-[5-(4-[[3-(trifluoromethyl)phenyl]methyl]piperazine-1-carbonyl)-2,3-dihydro-1H-indol-1-yl]ethan-1-one |
87% residual activity at 0.01 mM |
|
3.6.1.54 | 1-[5-[4-(3-bromophenyl)piperazine-1-sulfonyl]-2,3-dihydro-1H-indol-1-yl]ethan-1-one |
24% residual activity at 0.01 mM |
|
3.6.1.54 | 1-[5-[4-(3-ethylphenyl)piperazine-1-carbonyl]-2,3-dihydro-1H-indol-1-yl]ethan-1-one |
21% residual activity at 0.01 mM |
|
3.6.1.54 | 1-[5-[4-(3-hydroxyphenyl)piperazine-1-sulfonyl]-2,3-dihydro-1H-indol-1-yl]ethan-1-one |
91% residual activity at 0.01 mM |
|
3.6.1.54 | 1-[5-[4-([1,1'-biphenyl]-3-yl)piperazine-1-carbonyl]-2,3-dihydro-1H-indol-1-yl]ethan-1-one |
24% residual activity at 0.01 mM |
|